Session Title: GTN and Pricing Visibility

Session Description: Streamlining the process of gross-to-net and government price modeling is critical for specialty drugs that are entertaining new channel designs or facing increased pressure to contract. Manufacturers may need to model a change in contract terms, a change in channel strategy, or increases or decreases in patient support programs. For this, they require access to data for nearly any fee and price concession including channel service fees, patient support program utilization, and any rebate or administrative fee. Listen to industry leader Jennifer Sharpe, MBA and Kinneret Klein, Commercial Financial Planning and Analysis Director at Kyowa Kirin discuss best practices for sourcing the data needed for “what if” analytics, including channel service fees, patient support program utilization, and any rebate or administrative fee.